If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,328.04 today based on a ...
BioSpace7h
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Alnylam initiated with a Buy at Redburn Atlantic
Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...
Alnylam presents new data from HELIOS-B Phase 3 trial
Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer
Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...
Alnylam Stock Jumps After the FDA Approves Its Heart Drug
Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip
Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Alnylam wins FDA approval for rare heart disease drug
Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...
BioPharma Dive10d
Alnylam drug gets long-awaited FDA approval in deadly heart disease
Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...
FDA approves new drug to treat protein buildup in the heart
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
Business Wire2d
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark ...